Op-Ed: Expand Patient Choice to Lower Medication Costs
Role: Content Strategy & Executive Thought Leadership
The Strategy: In the highly regulated rheumatology space, brand authority is built through advocacy. I worked with Articularis leadership to synthesize complex congressional testimony into a high-impact narrative focused on the "biosimilar paradox." The strategy was to bridge the gap between clinical efficacy and the economic realities of independent practice, framing biosimilar adoption not just as a medical choice, but as a necessary policy shift to protect patient access and independent medicine.
The Result: The piece successfully established Articularis as a vocal leader in the national drug-pricing debate. By aligning the brand with key industry "pain points"—such as PBM transparency and Medicare reimbursement flaws—the op-ed generated significant engagement among specialty healthcare stakeholders and reinforced the group’s commitment to sustainable, independent physician leadership.
